Lec 13- Medicines for children Flashcards
(39 cards)
Medicine development
Against the odds
- Odds are 13.8% (Phase I to approval)
- Cost is >$1,400,000,000 plus >$300,000,000 post-approval research
- Discovering and developing a new medicine is challenging, and developing paediatric medicines is very difficult indeed
Timeline for pharmaceuticals

The paediatric medicines market
Small humans, big needs
- Large market- 20% of the EU population, 100 million individuals, less than 18-year-old
- Poorly served market
- Comparatively small market size
- Logistical challenges and technical difficulties have been a disincentive for major pharmaceutical companies from addressing the needs of the paediatric market
- Disease burden highest in adults
- Between 50-90% of medicines have not been developed for children
- As a result, most use involves off-label usage of products that are not in an age-appropriate formate i.e. specials, extemporaneous preparations, manipulated adult forms
Coping mechanism
- Mix- hide in food
- Mask: Preceed or follow medicine with a flavour
- Physical force
- Bribery- money
- Improve palatability- flavour enhancement (flavour ex)
Coping mechanisms
- 53% use coping mechanisms (170 children)
- Use of coping mechanisms significantly correlates (95%) with
- How pleasant medicines is to take
- Whether medicine makes a child feel unwell
- 71% of children who said their medicines did not taste ok, used coping mechanisms
- 76.9% of children who said their medicines tasted ok didn’t use coping mechanisms
Perspective
- Identify and prioritise the needs
- Industry, Academia, HCPs, Regulatory authorities, Patient advocacy groups
- Address the needs
- Pharma scientists in industry and academia have a responsibility to design and develop age-appropriate formulations
- Clinical development in industry and academia to deliver the clinical evidence
- Sustainability
- Support in prescribing and dispensing practice from HCPs incentivises and sustains R&D and supply
- Health technology assessment HTA authorities for pricing and reimbursement alignment with regulatory authorities
- Influencers support of the value fo paediatric specific medicines
Current paediatric regulation
- To promote the development of products and prescribing information to meet the specific needs of children
- The intent is to do this without
- Delaying approval of products in for adult population
- Conducting unnecessary studies
- The intent is to do this without
- Incentives for industry (IP) balanced against requirements (for completion of paediatric studies)
- Scope
- New products
- Existing products with remaining IP
- Off patent active ingredient PUMA (Paediatric Use Marketing Authorisation)
Summary of Paediatric regulation

Have the regulations made any impact
- 8 PUMAs made in 12 years- good but not a huge change
*
Special considerations in this special population
Special considerations
- Cater for appropriate paediatric sub-population
- Pre-term newborn infants
- Term newborn infants (0-28 days)
- Infants & Toddlers (>28 days to 23 months)
- Children (2-11 years)
- Adolescents
- Physiological and ADME differences between children and adults
- Developmental variability through to adulthood
- Careful when using age or weight criteria alone
- Development of specific formulations for paediatric dosing
- Children’s medication adherence
- Acceptibility of dose form and dose administration
- Excipient toxicity
Know your patient
physiology
- There are pH differences which influence ADME
- These factors need to be considered

Summary of GI tract pH data

At-risk groups
Potential oral sensory problems
- Pre-maturity- At risk due to having potentially aversive experiences, e.g. tube-feeding, sucking out, exhaustion (no suckling)
- Neurological disorders- Oromotor, dysphagia and sensory abnormalities, e.g. cerebral palsy or issues are seen with a syndrome where hypotonicity and hypersensitivity are a problem
- Developmental delay- Can result in delayed feeding development
- Pro-longed and complex medical intervention- Psychological impact of prolonged or invasive medical treatment e.g. NG tube, frequent N+V
- Metabolic, liver and kidney diseases- Growing evidence of disturbances of taste perception and appetite.Part of the larger group exposed to prolonged medical interventions and periods of feeling unwell
- ENT disorders and unusual structure and function- Physical difficulties with feeding and swallowing which can result in disturbances in feeding development
Territory, location and timing
- Do the children in all intended territories have similar access to clean water? What impact does this have on products designed to require reconstitution before use
- What dosage forms are children in the intended territories more familiar with
- Are multi-use packs more convenient for the patient than single-use packs
- Is intended administration in a hospital, at home, at school, in public
- Frequency and timing of dosing e.g. emergency rescue treatment
Preferences
- Patient-centered
- Acceptable to achieve adherence
- Willing participation in taking the medication
- On a routine basis in chronic treatment
- Acceptable to achieve adherence
- Administration friendly
- Convenient and easy to measure dose, and administer or take
- Without modification or coping mechanisms
- Individual preferences
- Many external factors which have shaped, and continue to shape preferences
- One size (preference) doesn’t fit all
- What children would prefer may clash with adult paradigm and regulation
Which dose form do children prefer
- Liquid vs Solid Oral
- Logical deduction= nice tasting liquid
- However, 8yr old CF patient describes her repulsion to medicines which produce gag reflex
- A 7yr old neurology patient describes her decision to take tablets and refusal to take liquids
- ARV medication- tablets predominant
- In contrast, a number would simply prefer a nicer tasting liquid
- Raises value of choice and flexible-dose forms
Dose form considerations
- Medication adherence considerations
- Solutions/suspensions- palatability
- Solid oral dosage forms- ability to swallow
- Orodispersible films and tablets
- Ear/Eye drops- discomfort
- Intranasal- taste
- Suppositories- cultural acceptance
- IV- needle-phobia
- Inhalation- training, drug deposition
- HCP preconceptions and familiarity with dose form
- Development of medicines that can facilitate adherence
- Skin patches
- MR dosage forms- reduced dose frequency
- Device
Commercial products- our goal
Evidence-based prescribing & dispensing
- Registered ‘paediatric optimized’ commercial products provide the optimum solution
- Acceptability
- Ease of administration
- Evidence of key clinical parameters- safety, efficacy and dose
- Minimise imprecision and medication errors
- Control of quality up to and including the point of use
- Post-marketing pharmacovigilance, med info
Multifactorial approach
Developing a TPP

- Therapeutic product profile
- Assessing all parameters in the setting the product will be used to develop optimum product for children
- Risk and benefit analysis
Taste masking oral products
- Bitter blockers and taste modifiers
- Sweeteners and flavouring systems
- Modification of API solubility
- Molecular barrier around the API
- Physical barrier around the API
Toxicity of excipients
- GRAS (Generally Regarded As Safe) concept- Adult focus
- Sweeteners- sucrose commonly used in liquid formulations; long term use promotes dental caries
- Preservatives- some commonly used preservatives in injectables and oral liquids may be toxic in children due to immature metabolism
- Solvent
- Ethanol is commonly used in liquid preparations; may cause acute intoxication or chronic toxicity
- Propylene glycol accumulation may occur in young children due to limited metabolic pathway
- Colouring agents- may be associated with hyperactivity
Step database
Safety and Toxicity of Excipients for Paediatrics

Accelerating and de-risking the production of a paediatric oral formulation





